Mulpleta

Active Ingredient(s): Lusutrombopag
FDA Approved: * July 31, 2018
Pharm Company: * SHIONOGI INC

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Mulpleta Overview

Lusutrombopag is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures. It is being manufactured and marketed in Japan by Shionogi under the trade name Mulpleta.[1][2][3] It was approved by the FDA in July 2018 and NICE in January 2020.[4][5&a...

Read more Mulpleta Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lusutrombopag

Recent Mulpleta Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Mulpleta: (1 result)

Sorted by National Drug Code

• 59630-551 Mulpleta 3 mg Oral Tablet, Film Coated by Shionogi Inc.

Other drugs which contain Lusutrombopag or a similar ingredient: (1 result)

• LUSUTROMBOPAG